^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1d
    Consistency of c-Met protein overexpression over time in patients with non-squamous non-small cell lung cancer. (PubMed, Histopathology)
    These results indicate c-Met protein overexpression can be assessed before or after treatment since most patients maintain consistent c-Met status. As targeted therapies may elevate c-Met overexpression over time, retesting may be necessary in those with an oncogenic driver alteration initially diagnosed as c-Met negative.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET overexpression • MET expression
    2d
    RTOG 1308: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=330, Active, not recruiting, Radiation Therapy Oncology Group | Trial completion date: Jan 2025 --> Nov 2028 | Trial primary completion date: Jan 2025 --> Nov 2028 | Completed --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    2d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    2d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    3d
    Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France. (PubMed, Cancer Med)
    This real-world study demonstrates the low frequency of HER2 testing and potential poor prognosis for patients diagnosed with LAM HER2m NSCLC in France between 2015 and 2020. Despite the low prevalence of HER2m NSCLC, these data highlight the importance of routine HER2 testing to enable patients with HER2m NSCLC to receive treatments that can improve clinical outcomes.
    Clinical data • Retrospective data • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    5d
    Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model. (PubMed, Health Technol Assess)
    Sequences starting with atezolizumab + bevacizumab + doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab + doublet platinum chemotherapy. Sequences starting with pemetrexed + platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years...46. See the NIHR Funding and Awards website for further award information.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • pemetrexed
    5d
    Explainable AI reveals squamous histology and U-shaped PD-L1 patterns as primary subgroup predictors of neoadjuvant and perioperative immunotherapy benefit in NSCLC: a machine learning analysis. (PubMed, Cancer Immunol Immunother)
    Our results suggest that for PD-L1-positive non-squamous cases, the added benefit of extended adjuvant therapy may be limited. However, given our reliance on aggregate data and trial-level imbalances, these findings remain hypothesis-generating and should not alter current clinical practice. Rather, they offer an exploratory framework to inform patient selection for future de-escalation trials.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    6d
    Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (clinicaltrials.gov)
    P1, N=60, Recruiting, University of Rochester | N=28 --> 60
    Enrollment change
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • pemetrexed
    6d
    PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    6d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)
    7d
    Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. (PubMed, Thorac Cancer)
    Systemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non-squamous NSCLC. These hypothesis-generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    7d
    CR-001-101: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors (2025-523590-42-00)
    P1/2, N=44, Not yet recruiting, Crescent Biopharma Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation